Skip to main content
Alicia Morgans, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

AliciaKatherineMorgansMD, MPH

Oncology Boston, MA

Genitourinary Oncology

Associate Professor of Medicine, Harvard Medical School Medical Director, Survivorship Program, Dana-Farber Cancer Institute

Dr. Morgans is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Morgans' full profile

Already have an account?

Education & Training

  • Vanderbilt University
    Vanderbilt UniversityMPH, 2013 - 2015
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineMPH, Epidemiology, 2013 - 2015
  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2006 - 2009
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2006
  • Ursinus College
    Ursinus CollegeBS, Biology and Spanish, Summa Cum Laude, 2002

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2009 - 2026
  • RI State Medical License
    RI State Medical License 2022 - 2024
  • IL State Medical License
    IL State Medical License 2017 - 2023
  • TN State Medical License
    TN State Medical License 2012 - 2018
  • PA State Medical License
    PA State Medical License 2006 - 2009
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Goldberger Scholarship Vanderbilt University School of Medicine, 2013
  • Honors in Biology Ursinus College, 2002
  • Valedictorian Ursinus College, 2002
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer  
    Pezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS..., Ann Oncol, 1/1/2017
  • Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction  
    Kanz BA, Pollack MH, Johnpulle RA, Puzanov I, Horn L, Morgans AK, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB, Journal for ImmunoTherapy of Cancer, 1/1/2016
  • Optimal management of muscle-invasive bladder cancer - a review  
    Scarpato KR, Morgans AK, Moses KA, Res Rep Urol, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Patient Expectations from Treatment of Incurable Metastatic Prostate Cancer.
    Morgans AK, Du L, Ahmed IA, Penson DF, Society of Medical Decision Making Annual Meeting, 1/1/2016
  • Anti-Tumor Activity, Safety and Pharmacokinetics (PK) of AGS15E (ASG-15ME) in a Phase I Dose Escalation Trial in Patients (Pts) with Metastatic Urothelial Cancer (mUC).
    D.P. Petrylak, E.I. Heath, G. Sonpavde, S. George, A. Morgans, B. Eigl, J. Picus, S. Cheng, S. Hotte, E. Gartner, M. Vincent, R. Chu, B. Anand, K. Morrison, L. Jackson..., American Society of Clinical Oncology Annual Meeting, 1/1/2016
  • Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).
    Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, Jarrard DF, Liu G, Morgans AK, Wong YN, Sweeney C, American Society of Clinical Oncology Annual Meeting, 1/1/2016
  • Join now to see all

Lectures

  • Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US c... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Biochemical Recurrence: Judicious Clinical Management of an Evolving Disease State. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • Optimizing Patient-Centered Care and Follow-up in Prostate Cancer 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Authored Content

  • Decision Analysis Defining Optimal Management of Clinical Stage 1 High-Risk Nonseminomatous Germ Cell Testicular Cancer with Lymphovascular InvasionMay 2018

Press Mentions

  • Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley Ross
    Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley RossJanuary 22nd, 2023
  • Advanced Prostate Cancer Practice Informing Data Presented at ASCO 2022 - Neeraj Agarwal
    Advanced Prostate Cancer Practice Informing Data Presented at ASCO 2022 - Neeraj AgarwalJanuary 5th, 2023
  • PORTOS as a Predictive Biomarker to Help Personalize Radiotherapy Dose in the Postoperative Setting, in the SAKK 09/10 Trial - Alan Dal Pra
    PORTOS as a Predictive Biomarker to Help Personalize Radiotherapy Dose in the Postoperative Setting, in the SAKK 09/10 Trial - Alan Dal PraDecember 5th, 2022
  • Join now to see all

Grant Support

  • Physician Research Training AwardDepartment of Defense2016–2020
  • Durden Foundation Creativity AwardProstate Cancer Foundation2016–2018

Professional Memberships

Hospital Affiliations